<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937675</url>
  </required_header>
  <id_info>
    <org_study_id>eFT508-0002</org_study_id>
    <nct_id>NCT02937675</nct_id>
  </id_info>
  <brief_title>A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies</brief_title>
  <official_title>A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Effector Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Effector Therapeutics</source>
  <brief_summary>
    <textblock>
      This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and
      cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and
      antitumor activity of eFT508. The study will evaluate oral daily administration of eFT508.
      Treatment and study subject evaluation will be performed in 21-day cycles.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose and/or Recommended Dose within the tested eFT508 dose range</measure>
    <time_frame>up to one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>up to three years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>eFT508 Escalation Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This portion of the study will evaluate the safety and pharmacology of a range of eFT508 doses administered daily in subjects with previously treated lymphomas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>eFT508 Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of eFT508 monotherapy in subjects with specific previously treated lymphomas</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eFT508</intervention_name>
    <arm_group_label>eFT508 Escalation Cohort</arm_group_label>
    <arm_group_label>eFT508 Expansion Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          2. Presence of an active hematological malignancy.

          3. Presence of measurable disease.

          4. Hematological malignancy has been previously treated, has relapsed after or progressed
             during prior therapy, and has limited potential for benefit from currently available
             therapy including hematopoietic stem cell transplantation.

          5. At least 2 weeks post any treatments/therapies at the time of first dose.

          6. Adequate bone marrow function.

          7. Adequate hepatic function.

          8. Adequate renal function.

          9. Normal coagulation panel.

         10. Negative antiviral serology.

         11. Willingness to use effective contraception.

        Exclusion Criteria:

          1. Central nervous system malignancy

          2. Gastrointestinal disease

          3. Significant cardiovascular disease

          4. Significant ECG abnormalities.

          5. Ongoing risk for bleeding due to active peptic ulcer disease, bleeding diathesis or
             requirement for systemic anticoagulation

          6. Ongoing systemic bacterial, fungal, or viral infection (including upper respiratory
             tract infections)

          7. Pregnancy or breastfeeding.

          8. Major surgery within 4 weeks before the start of study therapy.

          9. Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids

         10. Use of drugs that could prolong the QT interval within 7 days before the start of
             study therapy.

         11. Use of drugs that might pose a risk of a drug-drug interaction within 2-7 days before
             the start of study therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Barton, MD</last_name>
    <role>Study Director</role>
    <affiliation>CMO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cara Casseday</last_name>
    <phone>619-990-8136</phone>
    <email>ccasseday@effector.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debra T Vallner, PhD, MBA</last_name>
    <phone>650-619-0015</phone>
    <email>dvallner@effector.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samuel Oschin comprehensive Cancer Institute at Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tu Nguyen, CRC</last_name>
      <phone>310-423-0192</phone>
      <email>Tu.Nguyen@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Bethany Wendel, RN</last_name>
      <phone>310-967-4339</phone>
      <email>Bethany.Wendel@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Yuliya Linhares, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Jones</last_name>
      <phone>615-329-7413</phone>
      <email>djones@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Manish Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vidya Yarlagadda, MS, CCRP</last_name>
      <phone>313-576-9772</phone>
      <email>yarlagas@karmanos.org</email>
    </contact>
    <contact_backup>
      <last_name>Christy Houde</last_name>
      <phone>313-576-9381</phone>
      <email>houdec@karmanos.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rod Ramchandren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Adams</last_name>
      <phone>313-916-8862</phone>
      <email>nadams9@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Kris Strzalkowsi</last_name>
      <phone>313-916-7450</phone>
      <email>kstrzal1@hfhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ding Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Deno</last_name>
      <email>Deno.Dawn@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Nora Bennani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Batarse, MS</last_name>
      <phone>585-275-5825</phone>
      <email>Frances_Batarse@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Barr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne O'Malley</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>208</phone_ext>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Hannah Crocker</last_name>
      <phone>330-492-3345</phone>
      <phone_ext>207</phone_ext>
      <email>hcrocker@gabrailcancercenter.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Goetz, RN</last_name>
      <email>Erica.Goetz@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Moshe Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Rasmussen, BS, CCRC</last_name>
      <phone>206-288-7140</phone>
      <email>hrasmuss@seattlecca.org</email>
    </contact>
    <investigator>
      <last_name>Ajay Gopal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia McEwuen</last_name>
      <email>smcewuen@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Abraham Kanate, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>small molecule inhibitor of protein translation</keyword>
  <keyword>immunomodulator</keyword>
  <keyword>phase 1 dose escalation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

